Skip to main content

SRTS

Stock
Health Care
Medical Devices

Performance overview

SRTS Price
Price Chart

Forward-looking statistics

Beta
1.15
Risk
82.26%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.

Company info

SectorHealth Care
IndustryMedical Devices
Employees39
Market cap$90.3M

Fundamentals

Enterprise value$64.5M
Revenue$39.5M
Revenue per employee
Profit margin4.56%
Debt to equity0.86

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.11
Dividend per share
Revenue per share$2.42
Avg trading volume (30 day)$317K
Avg trading volume (10 day)$294K
Put-call ratio

Macro factor sensitivity

Growth+11.7
Credit+0.1
Liquidity-7.3
Inflation+10.8
Commodities+3.5
Interest Rates-1.5

Valuation

Dividend yield0.00%
PEG Ratio8.03
Price to sales1.94
P/E Ratio8.03
Enterprise Value to Revenue1.63
Price to book2.98

Upcoming events

Next earnings dayMay 16, 2025
Next dividend day
Ex. dividend day

News

Why Sensus Healthcare, Inc. (SRTS) Outpaced the Stock Market Today

Sensus Healthcare, Inc. (SRTS) reached $4.44 at the closing of the latest trading day, reflecting a +2.54% change compared to its last close.

Zacks Investment Research (July 17, 2025)
Sensus Healthcare, Inc. (SRTS) Declines More Than Market: Some Information for Investors

Sensus Healthcare, Inc. (SRTS) closed at $4.64 in the latest trading session, marking a -2.11% move from the prior day.

Zacks Investment Research (July 1, 2025)
Is It Worth Investing in Sensus Healthcare (SRTS) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks Investment Research (June 4, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free